Search Results

Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials—data from the prospective German Tumour Registry Lymphatic Neoplasms.

• Authors : and the TLN-Group (Tumour Registry Lymphatic Neoplasms); Knauf, Wolfgang; Aldaoud, Ali

• Source: Annals of Hematology; Dec2018, Vol. 97 Issue 12, p2437-2445, 9p

Record details

Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.

• Authors : Knauf, Wolfgang; Aldaoud, Ali; Hutzschenreuter, Ulrich

• Source: Annals of Hematology; Aug2018, Vol. 97 Issue 8, pN.PAG-N.PAG, 1p

Record details

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms.

• Authors : Cvetković M; Clinic of Hematology, University Clinical Centre of Serbia, 2 Dr Koste Todorovića, Belgrade, 11000, Serbia. .; Arsenović I

Subjects: Neutrophils* ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/blood ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/diagnosis

• Source: Annals of hematology [Ann Hematol] 2024 Nov; Vol. 103 (11), pp. 4545-4556. Date of Electronic Publication: 2024 Sep 27.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Myeloproliferative neoplasms: young patients, current data and future considerations.

• Authors : Sobas M; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. .; Ianotto JC

Subjects: Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/therapy ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/diagnosis ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/genetics

• Source: Annals of hematology [Ann Hematol] 2024 Sep; Vol. 103 (9), pp. 3287-3291. Date of Electronic Publication: 2024 Aug 07.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.

• Authors : Soboń A; Department of Hematology, Institute of Hematology and Transfusion Medicine, Indira Gandhi Str. 14, 02-776, Warsaw, Poland.; Drozd-Sokołowska J

Subjects: COVID-19*/COVID-19*/COVID-19*/etiology ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy; Adult

• Source: Annals of hematology [Ann Hematol] 2023 Aug; Vol. 102 (8), pp. 2119-2126. Date of Electronic Publication: 2023 Jul 01.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Myeloid sarcoma: more and less than a distinct entity.

• Authors : Loscocco GG; Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; Doctorate School GenOMec, University of Siena, Siena, Italy.

Subjects: Sarcoma, Myeloid*/Sarcoma, Myeloid*/Sarcoma, Myeloid*/diagnosis ; Sarcoma, Myeloid*/Sarcoma, Myeloid*/Sarcoma, Myeloid*/genetics ; Sarcoma, Myeloid*/Sarcoma, Myeloid*/Sarcoma, Myeloid*/therapy

• Source: Annals of hematology [Ann Hematol] 2023 Aug; Vol. 102 (8), pp. 1973-1984. Date of Electronic Publication: 2023 Jun 07.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.

• Authors : Pulanić D; Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Kispaticeva 12, 10 000, Zagreb, Croatia. .; Bátorová A

Subjects: Purpura, Thrombocytopenic, Idiopathic*/Purpura, Thrombocytopenic, Idiopathic*/Purpura, Thrombocytopenic, Idiopathic*/drug therapy ; Purpura, Thrombocytopenic, Idiopathic*/Purpura, Thrombocytopenic, Idiopathic*/Purpura, Thrombocytopenic, Idiopathic*/chemically induced ; COVID-19*

• Source: Annals of hematology [Ann Hematol] 2023 Apr; Vol. 102 (4), pp. 715-727. Date of Electronic Publication: 2023 Feb 24.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma.

• Authors : Swoboda R; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.; Giebel S

• Source: Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1919.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print Cited Medium: Internet ISSN: 1432-0584

Record details

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.

• Authors : Swoboda R; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.; Giebel S

Subjects: Salvage Therapy*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Hodgkin Disease/Hodgkin Disease/Hodgkin Disease/*drug therapy

• Source: Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1755-1767. Date of Electronic Publication: 2021 Feb 24.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.

• Authors : Breccia M; Hematology, Department of Precision and Translational Medicine, Policlinico Umberto 1, Sapienza University, Rome, Italy. .; Baratè C

Subjects: Clinical Decision-Making*; Primary Myelofibrosis/Primary Myelofibrosis/Primary Myelofibrosis/*drug therapy ; Pyrazoles/Pyrazoles/Pyrazoles/*administration & dosage

• Source: Annals of hematology [Ann Hematol] 2020 Jan; Vol. 99 (1), pp. 65-72. Date of Electronic Publication: 2019 Dec 12.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details